8-K: Wellgistics Health Enters Consulting Agreement and Expands Healthcare Ecosystem with Tollo Health Partnership

Wellgistics Health, Inc. has entered into a consulting agreement with Hudson Global Ventures, LLC and partnered with Tollo Health, LLC to market medical food products for GLP-1 treatment side effects and Long COVID.

Summary

• Wellgistics Health, Inc. entered into a consulting agreement with Hudson Global Ventures, LLC on February 25, 2025, for business advisory services, growth strategy guidance, and networking opportunities.
• Hudson will receive $250,000 and 52,000 shares of Wellgistics Health's common stock as compensation.
• Wellgistics Health will provide Hudson with notice and registration rights for the resale of its shares.
• On February 26, 2025, Wellgistics Health announced a partnership with Tollo Health, LLC to market medical food products for GLP-1 treatment-related side effects and Long COVID.
• Tollo's products include Galectovid, a medical food for Galectin-1 & 3 associated viral infections.
• The GLP-1 drug market is valued at $46.7 billion and is expected to reach $322 billion by 2034.
• Approximately 16 million working-age Americans have Long COVID, resulting in an estimated $170 billion in lost wages annually.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with new partnerships and market expansion, but also acknowledges risks associated with forward-looking statements.

Positives

• The consulting agreement with Hudson Global Ventures could provide valuable business advisory services and networking opportunities.
• The partnership with Tollo Health expands Wellgistics Health's product offerings into the growing medical food market.
• The focus on GLP-1 side effects and Long COVID addresses significant and growing healthcare needs.
• Tollo's products are supported by scientific research and have a Generally Recognized As Safe (GRAS) safety profile.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• The company's ability to meet distribution expectations and projections is uncertain.
• Market conditions could impact the success of the Tollo Health partnership.
• The consulting agreement with Hudson Global Ventures could be costly.

Future Outlook

The company expects the cross-selling strategy with Tollo Health to grow its customer base and position it as a key supplier in the GLP-1 and Long COVID markets.

Management Comments

• 'We are excited to partner with the team at Tollo, who bring in-depth scientific and medical knowledge in both the areas of muscle loss and chronic viral infections,' said Jason Lang, Vice President of Business Development of Wellgistics LLC.
• Gerald Commissiong, CEO of Tollo, stated that Wellgistics LLC is the 'ideal partner to help drive adoption in the healthcare practitioner market as we roll out our suite of medical foods in the United States.'

Industry Context

The partnership with Tollo Health positions Wellgistics Health to capitalize on the growing demand for solutions addressing GLP-1 side effects and Long COVID, aligning with the trend of personalized and integrated healthcare solutions.

Comparison to Industry Standards

• Wellgistics' move into medical foods mirrors trends seen with companies like Nestle Health Science and Abbott, who have invested heavily in medical nutrition.
• The focus on GLP-1 side effects is similar to strategies employed by companies like Zealand Pharma, which are developing specific treatments for obesity-related complications.
• The partnership with Tollo Health is similar to other pharmaceutical companies partnering with smaller companies to expand their product offerings.

Stakeholder Impact

• Shareholders may benefit from the potential growth and revenue opportunities resulting from the Tollo Health partnership.
• Pharmacies in Wellgistics LLC's network will have access to new medical food products to offer their patients.
• Patients may benefit from the availability of new solutions for managing GLP-1 side effects and Long COVID.

Next Steps

• Wellgistics LLC will prepare materials to market Tollo's products to its network of pharmacies.
• Wellgistics LLC plans to work with Tollo and its clients to generate industry-leading data on Tollo's suite of products.
• Tollo Health aims to bring to market a full range of products that will provide patients with functional relief from these devastating health conditions by addressing the key biological mechanisms driving poor patient outcomes.

Key Dates